drugset / Trial / NCT01167699

Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain

NCT01167699

Phase 3 Completed 174 enrolled Mundipharma Pharmaceuticals B.V.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of the study is to evaluate the patient preference for pain treatment with respect to quality of life in patients with moderate to severe non malignant pain. Patients who have insufficient pain relief and/or unacceptable side effects with the previous analgesic treatment WHO step 1 or 2 and require around-the-clock opioid therapy can be included in the study. The WHO step I or II analgesics will be compared with the new study medication OXN (oxycodone/naloxone).

Timeline

Start
2009-06
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule
Subject Oxycodone Other / unclassified

Indications

No indication recorded.